180 related articles for article (PubMed ID: 8704806)
21. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
22. Rationale for very high-dose chemotherapy with peripheral blood stem cell support in advanced ovarian cancer.
Panici PB; Scambia G; Baiocchi G; Laurelli G; Greggi S; Battaglia F; Ragusa G; Salerno G; Gallo A; Cento R
Haematologica; 1990; 75 Suppl 1():87-9. PubMed ID: 1972136
[TBL] [Abstract][Full Text] [Related]
23. [High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast cancer].
Martín M; Casado A; Llorente L; López Martín JA; Rodríguez Lescure A; Nieto Y; Ayala F; Pérez Calvo J; Alonso JL; Pérez López C; Villegas A; Díaz-Rubio E
Med Clin (Barc); 1997 Dec; 109(20):775-81. PubMed ID: 9493155
[TBL] [Abstract][Full Text] [Related]
24. [Treatment outcome and prognosis of autologous hematopoietic stem cell transplantation combined with high dose radiotherapy/chemotherapy in 22 patients with nasal NK/T cell lymphoma].
Cui XZ; Wang HQ; Liu XM; Zhang HL; Li W
Zhonghua Xue Ye Xue Za Zhi; 2007 Sep; 28(9):609-11. PubMed ID: 18246818
[TBL] [Abstract][Full Text] [Related]
25. High-dose chemotherapy with autologous bone marrow support as consolidation after standard-dose adjuvant therapy in primary breast cancer patients with seven or more involved axillary lymph nodes.
Lalisang RI; Hupperets PS; ten Haaft MA; Jansen RL; Schouten HC
Bone Marrow Transplant; 1998 Feb; 21(3):243-7. PubMed ID: 9489646
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
[TBL] [Abstract][Full Text] [Related]
27. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
Visani G; Lemoli R; Tosi P; Martinelli G; Testoni N; Ricci P; Motta M; Gherlinzoni F; Leopardi G; Pastano R; Rizzi S; Piccaluga P; Isidori A; Tura S
Bone Marrow Transplant; 1999 Sep; 24(5):467-72. PubMed ID: 10482929
[TBL] [Abstract][Full Text] [Related]
28. [High-dose chemotherapy and autologous bone marrow transplantation in solid tumors. A review].
Handberg J; Hansen SW
Ugeskr Laeger; 1996 Jul; 158(29):4175-80. PubMed ID: 8701532
[TBL] [Abstract][Full Text] [Related]
29. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
Crump M; Gluck S; Tu D; Stewart D; Levine M; Kirkbride P; Dancey J; O'Reilly S; Shore T; Couban S; Girouard C; Marlin S; Shepherd L; Pritchard KI
J Clin Oncol; 2008 Jan; 26(1):37-43. PubMed ID: 18025439
[TBL] [Abstract][Full Text] [Related]
30. Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999.
Pedrazzoli P; Ferrante P; Kulekci A; Schiavo R; De Giorgi U; Carminati O; Marangolo M; Demirer T; Siena S; Rosti G;
Bone Marrow Transplant; 2003 Sep; 32(5):489-94. PubMed ID: 12942095
[TBL] [Abstract][Full Text] [Related]
31. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group.
Koscielniak E; Klingebiel TH; Peters C; Hermann J; Burdach ST; Bender-Götze C; Müller-Weihrich ST; Treuner J
Bone Marrow Transplant; 1997 Feb; 19(3):227-31. PubMed ID: 9028550
[TBL] [Abstract][Full Text] [Related]
32. High-dose chemotherapy with autologous hematopoietic stem cell support for solid tumors in adults.
Pedrazzoli P; Rosti G; Secondino S; Carminati O; Demirer T; ; ;
Semin Hematol; 2007 Oct; 44(4):286-95. PubMed ID: 17961729
[TBL] [Abstract][Full Text] [Related]
33. [High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich].
Jost LM; Honegger HP; Stahel RA
Schweiz Med Wochenschr; 2000 Jan; 130(3):60-9. PubMed ID: 10683881
[TBL] [Abstract][Full Text] [Related]
34. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
Peters WP; Rosner GL; Vredenburgh JJ; Shpall EJ; Crump M; Richardson PG; Schuster MW; Marks LB; Cirrincione C; Norton L; Henderson IC; Schilsky RL; Hurd DD
J Clin Oncol; 2005 Apr; 23(10):2191-200. PubMed ID: 15767638
[TBL] [Abstract][Full Text] [Related]
35. High-dose therapy in breast cancer: out of favor but not out of promise.
Glück S; Stewart D
Bone Marrow Transplant; 2000 May; 25(10):1017-9. PubMed ID: 10828859
[TBL] [Abstract][Full Text] [Related]
36. The sound and the fury: an update on the role of high-dose chemotherapy and autologous stem cell salvage for both metastatic and high-risk breast cancer.
Bar MH
Conn Med; 2000 Jan; 64(1):3-6. PubMed ID: 10697358
[No Abstract] [Full Text] [Related]
37. Autologous bone marrow support and bone disease in metastatic breast cancer.
Nabholtz JM; al-Tweigeri T; Jacquelin N; Venner PM
Can J Oncol; 1995 Dec; 5 Suppl 1():33-9. PubMed ID: 8853522
[TBL] [Abstract][Full Text] [Related]
38. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.
Rodríguez J; Conde E; Gutiérrez A; Arranz R; Gandarillas M; Leon A; Ojanguren J; Sureda A; Carrera D; Bendandi M; Moraleda J; Ribera JM; Albo C; Morales A; García JC; Fernández P; Cañigral G; Bergua J; Caballero MD;
Eur J Haematol; 2007 Apr; 78(4):290-6. PubMed ID: 17378891
[TBL] [Abstract][Full Text] [Related]
39. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation.
Schetelig J; Fetscher S; Reichle A; Berdel WE; Beguin Y; Brunet S; Caballero D; Majolino I; Hagberg H; Johnsen HE; Kimby E; Montserrat E; Stewart D; Copplestone A; Rösler W; Pavel J; Kingreen D; Siegert W
Haematologica; 2003 Nov; 88(11):1272-8. PubMed ID: 14607756
[TBL] [Abstract][Full Text] [Related]
40. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
Cheng YC; Rondón G; Yang Y; Smith TL; Gajewski JL; Donato ML; Shpall EJ; Jones R; Hortobagyi GN; Champlin RE; Ueno NT
Biol Blood Marrow Transplant; 2004 Nov; 10(11):794-804. PubMed ID: 15505610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
